


What is claim d is:

1. A therapeutical method comprising administration of a composition comprising an amount of oligo- β -(1,3)-glucan and a pharmaceutically acceptable carrier, to a human being or to a warm-blood animal suffering from a disease selected from the group consisting in a tumor, a cancer, a viral disease, a bacterial disease, a fungal disease, a disease of the immune system, an auto-immune disease or a disease related to a deficiency of immunostimulation, wherein the amount of oligo- β -(1,3)-glucan is effective to treat the disease.

2. The method according to claim 1, wherein the oligo- β -(1,3)-glucan is a compound presenting the following formula (1):



in which $n=1$ to 7, preferably, $n=2$ or $n=3$,
or a pharmaceutically acceptable salt thereof.

3. The method according to claim 2, wherein the compound of formula 1 is Laminaritetraose ($n=2$) or Laminaripentaose ($n=3$).

4. The method of claim 1, wherein the cancer is breast cancer, lung cancer, oesophagus cancer, stomach cancer, intestinal cancer or colon cancer.

5. The method according to claim 1, wherein the administration of oligo- β -(1,3)-glucan stimulates NK cells in the human being or the warm-blood animal.

6. The method according to claim 1, wherein the administration of oligo- β -(1,3)-glucan stimulates the

production of TNF-alpha in the human being or the warm-blood animal.


7. The method according to claim 1, wherein the composition is administered intravenously, intraperitoneally, or orally to the patient.

8. The method according to claim 1, further comprising administration of a chemotherapeutic agent.

9. The method according to claim 1, further comprising administration of a potentiator.

10. The method according to claim 1, wherein the composition is under the form of a solution, suspension, syrup, tablet, capsule, injections, ointment, pulmonary spray.

11. Pharmaceutical composition under the form of a solution, suspension, spray, aerosol, tablet, capsule, injection, ointment, pulmonary aerosol comprising a therapeutically effective amount of oligo-1-3- β -glucan of formula (1)



in which $n=1$ to 7, preferably $n=2$ or $n=3$,
or a salt pharmaceutically acceptable salt thereof,
and a pharmaceutical acceptable carrier,
said composition being free of any other glucan.